Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury

Gastroenterology

Volumn 141, Issue 5, 2011, Pages 1665-1672.e9

  Davern, Timothy J ^a   Chalasani, Naga ^b   Fontana, Robert J ^c   Hayashi, Paul H ^d   Protiva, Petr ^e   Kleiner, David E ^f   Engle, Ronald E ^g   Nguyen, Hanh ^g   Emerson, Suzanne U ^g   Purcell, Robert H ^g   Tillmann, Hans L ^h   Gu, Jiezhun ^h   Serrano, Jose ⁱ   Hoofnagle, Jay H ⁱ  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cirrhosis; Drug Toxicity; Liver Disease; Treatment

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS E; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TOXIC HEPATITIS; UNITED STATES;

EID: 80054848088     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.07.051     Document Type: Article

References (38)

1. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006;43:618-631.
2. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-742.
3. Emerson SU, Purcell RH. Hepatitis E virus. Rev Med Virol 2003;13:145-154.
4. Schlauder GG, Dawson GJ, Erker JC, et al. The sequence and phylogenetic analysis of a novel hepatitis E virus isolated from a patient with acute hepatitis reported in the United States. J Gen Virol 1998;79:447-456.
5. Levine DF, Bendall RP, Teo CG. Hepatitis E acquired in the UK. Gut 2000;47:740.
6. Ijaz S, Arnold E, Banks M, et al. Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis 2005;192:1166-1172.
7. Mansuy JM, Peron JM, Abravanel F, et al. Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol 2004;74:419-324.
8. Dalton HR, Fellows HJ, Gane EJ, et al. Hepatitis E in New Zealand. J Gastroenterol Hepatol 2007;22:1236-1240.
9. Halbur PG, Kasorndorkbua C, Gilbert C, et al. Comparative pathogenesis of infection of pigs with hepatitis E viruses recovered from a pig and a human. J Clin Microbiol 2001;39:918-923.
10. Yazaki Y, Mizuo H, Takahashi M, et al. Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food. J Gen Virol 2003;84:2351-2357.
11. Matsuda H, Okada K, Takahashi K, et al. Severe hepatitis E virus infection after ingestion of uncooked liver from a wild boar. J Infect Dis 2003;188:944.
12. Wichmann O, Schimanski S, Koch J, et al. Phylogenetic and case-control study on hepatitis E virus infection in Germany. J Infect Dis 2008;198:1732-1741.
13. Meng XJ, Wiseman B, Elvinger F, et al. Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol 2002;40:117-122.
14. Kuniholm MH, Purcell RH, McQuillan GM, et al. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis 2009;200:48-56.
15. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007;26:1429-1435.
16. Fontana RJ, Watkins PB, Bonkovsky HL, et al.; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55-68.
17. Chalasani N, Fontana RJ, Bonkovsky HL, et al.; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-1934.
18. Rockey DC, Seeff LB, Rochon J, et al.; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51:2117-2126.
19. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of International Consensus Meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
20. Engle RE, Yu C, Emerson SU, et al. Hepatitis E virus (HEV) capsid antigens derived from viruses of human and swine origin are equally efficient for detecting anti-HEV by enzyme immunoassay. J Clin Microbiol 2002;40:4576-4580.
21. Yu C, Engle RE, Bryan JP, et al. Detection of immunoglobulin M antibodies to hepatitis E virus by class capture enzyme immunoassay. Clin Diagn Lab Immunol 2003;10:579-586.
22. Johne R, Plenge-Bönig A, Hess M, et al. Detection of a novel hepatitis E-like virus in faeces of wild rats using a nested broadspectrum RT PCR. J Gen Virol 2010;91:750-758.
23. Meng XJ, Purcell RH, Halbur PG, et al. A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci U S A 1997;94:9860-9865.
24. Wang Y, Ling R, Erker JC, et al. A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis. J Gen Virol 1999;80:169-177.
25. Davern TJ, Chalasani N. Drug-induced liver injury in clinical trials: as rare as hens' teeth. Am J Gastroenterol 2009;104:1159-1161.
26. Krawczynski K. Hepatitis E. Hepatology 1993;17:932-941.
27. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008;48:494-503.
28. Dalton HR, Bendall R, Ijaz S, et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:698-709.
29. Chau TN, Lai ST, Tse C, et al. Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. Am J Gastroenterol 2006;101:292-296.
30. Dalton HR, Stableforth W, Thurairajah P, et al. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol 2008;20:784-790.
31. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811-817.
32. Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009;15:1225-1228.
33. Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferonalpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010;50:e30-e33.
34. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology 2010;139:1612-1618.
35. Chauhan A, Jameel S, Dilawari JB, et al. Hepatitis E virus transmission to a volunteer. Lancet 1993;341:149-150.
36. El-Sayed Zaki M, El-Deen Zaghloul MH, El Sayed O. Acute sporadic hepatitis E in children: diagnostic relevance of specific immunoglobulin M and immunoglobulin G compared with nested reverse transcriptase PCR. FEMS Immunol Med Microbiol 2006;48:16-20.
37. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E Vaccine. N Engl J Med 2007;357:895-903.
38. Zhu F-C, Zhang J, Zhang X-F, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376:895-902.